Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 6:25 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 385 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Transitional Cell Carcinoma of the Bladder Clear all

Conditions: Non-small Cell Lung Cancer, Gastric Cancer, Head and Neck Cancer, Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Bladder Urothelial Carcinoma, Colorectal Cancer, Esophageal Cancer, Hepatic Cancer, Renal Cell Carcinoma, Cholangiocarcinoma, Pancreatic Cancer, Other Solid Tumors
Interventions: CDX-585; Drug
Lead sponsor: Celldex Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 4
States / cities: Washington D.C., District of Columbia • Celebration, Florida • New York, New York + 1 more

Conditions: Urothelial Carcinoma Bladder
Interventions: Sasanlimab, Stereotactic Body Radiation Therapy, Radical Cystectomy + pelvic lymph node dissection + urinary diversion; Drug · Radiation · Procedure
Lead sponsor: The Methodist Hospital Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Urinary Bladder Neoplasms
Interventions: TAR-200, Cetrelimab; Drug · Biological
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 163 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 41
States / cities: Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 32 more

Conditions: Urothelial Carcinoma, Muscle-invasive Bladder Cancer
Interventions: Sacituzumab Govitecan (SG), Nivolumab; Drug
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Orange, California

Conditions: Muscle Invasive Bladder Urothelial Carcinoma
Interventions: Daily Adaptive External Beam Radiation Therapy; Radiation
Lead sponsor: Varian, a Siemens Healthineers Company; Industry
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Advanced Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Prostate Carcinoma, Metastatic Renal Pelvis Urothelial Carcinoma, Metastatic Ureter Urothelial Carcinoma, Metastatic Urethral Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Stage IV Bladder Urothelial Carcinoma AJCC v7, Stage IV Prostate Cancer AJCC v7, Stage IV Renal Pelvis Cancer AJCC v7, Stage IV Ureter Cancer AJCC v7, Stage IV Urethral Cancer AJCC v7, Unresectable Urothelial Carcinoma
Interventions: Bevacizumab, Cisplatin, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis, Placebo Administration; Biological · Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 506 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2021
U.S. locations: 872
States / cities: Birmingham, Alabama • Mobile, Alabama • Fairbanks, Alaska + 529 more

Conditions: Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm, Triple Negative Breast Cancer, Non-small Cell Lung Cancer, Esophageal Cancer, Pancreatic Cancer, Ovarian Cancer, Cervical Cancer, Head and Neck Squamous Cell Carcinoma, Prostate Cancer, Renal Pelvis Cancer, Bladder Cancer
Interventions: LY4052031, Pembrolizumab; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 460 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 22
States / cities: Duarte, California • La Jolla, California • Los Angeles, California + 15 more

Conditions: Urothelial Carcinoma Bladder, Bladder Cancer
Interventions: Gemcitabine, Docetaxel; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Urothelial Carcinoma
Interventions: Not listed
Lead sponsor: Tampere University Hospital; Other
Eligibility: 18 Years to 100 Years
Enrollment: 3,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Bladder Cancer
Interventions: aminophylline; Drug
Lead sponsor: University of Virginia; Other
Eligibility: 40 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Bladder Cancer
Interventions: induction cisplatin, induction 5-fluorouracil, induction gemcitabine, Induction BID radiation therapy, Induction QD radiation therapy, Consolidation BID radiation therapy, Consolidation QD radiation therapy, consolidation gemcitabine, consolidation 5-fluorouracil, consolidation cisplatin, radical cystectomy, Post-Induction Chemoradiotherapy Endoscopic Response Evaluation, adjuvant gemcitabine, adjuvant cisplatin; Drug · Radiation · Procedure
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years to 120 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2022
U.S. locations: 10
States / cities: Atlanta, Georgia • Boise, Idaho • Springfield, Illinois + 5 more

Conditions: Distal Urethral Cancer, Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Proximal Urethral Cancer, Recurrent Bladder Cancer, Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter, Recurrent Urethral Cancer, Regional Transitional Cell Cancer of the Renal Pelvis and Ureter, Stage III Bladder Cancer, Stage IV Bladder Cancer, Transitional Cell Carcinoma of the Bladder, Urethral Cancer Associated With Invasive Bladder Cancer
Interventions: ixabepilone; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Bladder Cancer, Urethral Cancer
Interventions: carboplatin, cisplatin, gemcitabine hydrochloride, paclitaxel, neoadjuvant therapy, radiation therapy; Drug · Procedure · Radiation
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2006
U.S. locations: 92
States / cities: Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 60 more

Conditions: Urothelial Carcinoma Bladder, Triple Negative Breast Cancer (TNBC), Hormone Receptor Positive Breast Adenocarcinoma, Non Small Cell Lung Cancer, Cervical Adenocarcinoma, Colorectal Adenocarcinoma, Head and Neck Cancer
Interventions: [225Ac]Ac-AKY-1189 (therapeutic), [64Cu]Cu-AKY-1189 (imaging); Drug
Lead sponsor: Aktis Oncology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 14
States / cities: Duarte, California • Irvine, California • Miami, Florida + 10 more

Conditions: Bladder (Urothelial, Transitional Cell) Cancer, Hematuria
Interventions: Headphones, Dwell time 5-10 minutes, Dwell Time more than 10 minutes; Device · Drug
Lead sponsor: Florian Schroeck; Federal
Eligibility: 18 Years and older
Enrollment: 1,740 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 5
States / cities: Birmingham, Alabama • Chapel Hill, North Carolina • Wilmington, North Carolina + 2 more

Conditions: Bladder Cancer, Muscle-Invasive Bladder Carcinoma, Urothelial Carcinoma, Pelvic Malignancy, Bladder Transitional Cell Carcinoma, Bladder Neoplasm
Interventions: Ureteral Stent Placement, No Ureteral Stent, Indocyanine Green with Fluorescence Imaging; Procedure · Diagnostic Test
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years to 85 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania

Conditions: Non-muscle Invasive Bladder Cancer
Interventions: ALT-801, Gemcitabine; Biological · Drug
Lead sponsor: Altor BioScience; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 5
States / cities: Birmingham, Alabama • Sacramento, California • Orlando, Florida + 2 more

Conditions: Metastatic Urothelial Carcinoma, Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma, Urothelial Cancer, Bladder Cancer
Interventions: Nogapendekin Alfa Inbakicept (NAI), enfortumab vedotin (EV), Pembrolizumab; Drug
Lead sponsor: ImmunityBio, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Metastatic Urothelial Carcinoma, Bladder Cancer
Interventions: Pembrolizumab, Cryoablation, Avelumab; Drug · Procedure
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Urothelial Carcinoma, Bladder Cancer
Interventions: Abiraterone acetate, Durvalumab, Methotrexate, Vinblastine, Doxorubicin Hydrochloride, Cisplatin; Other · Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 2
States / cities: Bloomington, Indiana • Houston, Texas

Conditions: Bladder Cancer, Metastatic Bladder Cancer, Unresectable Bladder Carcinoma, Urothelial Carcinoma
Interventions: Geriatric-8 Survey, National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Bladder Symptom Index-18 (FBISI-18), Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE®); Behavioral
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 65 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Urinary Bladder Neoplasms
Interventions: Cetrelimab, TAR-200, Cisplatin, Gemcitabine, Conventional radiation therapy, Hypo-fractioned radiation therapy; Biological · Drug · Radiation
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 518 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 28
States / cities: Loma Linda, California • Los Angeles, California • Santa Monica, California + 25 more

Conditions: Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Neoplasm Metastasis
Interventions: Vepugratinib, Placebo, EV, Pembrolizumab; Drug · Other
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2033
U.S. locations: 64
States / cities: Tucson, Arizona • Little Rock, Arkansas • Irvine, California + 48 more

Conditions: Gastric Adenocarcinoma, Adenocarcinoma of the Gastroesophageal Junction, Non-small Cell Lung Cancer, Carcinoma, Transitional Cell, Biliary Tract Cancer
Interventions: Ramucirumab, Pembrolizumab; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 7
States / cities: New Haven, Connecticut • Fort Myers, Florida • St. Petersburg, Florida + 3 more

Search by objective public record fields.

A Study of CDX-585 in Patients With Advanced Malignancies

Neoadjuvant Sasanlimab With Radiation as an in Situ Vaccine for Cisplatin-ineligible Muscle Invasive Bladder Cancer

A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder

Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma at High-Risk Recurrence

Daily Online Adaptive Short-Course Radiation Therapy and Concurrent Chemotherapy for Muscle-Invasive Bladder Cancer

Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

Intravesical Gemcitabine and Docetaxel for BCG naïve Non-muscle Invasive Bladder Cancer

Prospective Validation Study of High Volume Urine DNA Testing in Individuals With Suspicion of Urothelial Cancer

Study of BCG + Aminophylline Toxicity When Used in the Treatment of Bladder Cancer

Chemotherapy and Radiation Therapy in Treating Patients With Stage II or Stage III Bladder Cancer That Was Removed by Surgery

Ixabepilone in Treating Patients With Advanced Urinary Tract Cancer

S0121, Neoadjuvant Carboplatin, Paclitaxel, and Gemcitabine Followed by Cisplatin and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Carcinoma of the Urothelium

A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors

Effectiveness of Medical and Environmental Interventions to Reduce Cystoscopy Discomfort (CystoDiscomfort)

Clinical Trial to Evaluate Post-Operative Outcomes of Ureteral Stent vs Ureteral Stent Free Radical Cystectomy

A Study of ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-Muscle Invasive Bladder Cancer

N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer

Cryoablation With Pembrolizumab Or Avelumab In Urothelial Carcinoma

A Phase II Multicenter Study of Chemotherapy Versus Chemotherapy Plus Durvalumab (MEDI 4736) in Patients With Lymph Node Positive Urothelial Carcinoma of the Bladder

Management of Cisplatin-Ineligible Patients With Metastatic Bladder Cancer and The Role of Geriatric Assessments

A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder

A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer